Xeris Biopharma (XERS) closed at $10.07 on Oct 6, 2026, down 0.6% on the day. The stock is up 18.1% over the past month, up 16.1% over three months, up 28.3% year to date and up 22.8% over the past year. It trades 11.1% below its 52-week high of $11.33 and 91.8% above its 52-week low of $5.25. The close sits above its 50-day moving average ($8.53) and above its 200-day moving average ($7.23).
Yes — the Oct 6, 2026 close of $10.07 is 39.3% above the 200-day average of $7.23.
XERS closed 11.1% below its 52-week high of $11.33.
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
